Skip to content

Multicenter Prospective Cohort Study of Hodgkin Lymphoma

Multicenter Prospective Cohort Study of Hodgkin Lymphoma

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0004399
Enrollment
350
Registered
2019-10-30
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

National Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Never treated, newly diagnosed classical Hodgkin lymphoma patient by pathologic examination - age 18 and older - ECOG 0-2 - At least one measurable lesion (2cm or more on conventional CT or 1cm or more on spiral CT) - At least one identifiable uptake of nodes or extranodal lesion on FDG PET-CT - Adequate renal function (serum creatinine =2.5mg/dL, creatinine clearance = 50mL/min) - Adequate liver function (AST and ALT = 3 times of upper normal limit, bilirubin = 1.5 times of upper normal limit, alkaline phosphatase = 5 times of upper normal limit) - Adequate bone marrow function (ANC = 1,500/uL, platelet =75,000/uL, hemoglobin = 9.0g/dL) - Adequate cardiopulmonary function - Voluntary achieved informed consent approved by institutional review board

Exclusion criteria

Exclusion criteria: - Not correspond to inclusion criteria - Malignant tumor within 5 years of enrollment except skin basal cell carcinoma and cervix carcinoma in situ. - Clinically significant medical status (uncontrolled cardiac disease, history of myocardial infarction within 6 months of enrollment, uncontrolled pulmonary disease, significant neurological or psychological disease including dementia and epilepsy, uncontrolled active infection) - Pregnancy or breastfeeding, childbearing-age female without adequate contraception - Confirmed allergic response to drugs of present study - Not consent to present study

Design outcomes

Primary

MeasureTime frame
Overall survival

Secondary

MeasureTime frame
event free survival, progression free survival, overall response rate to initial therapy, overall response rate to induction therapy, clinical characteristics (prognosis related factors), toxicity profile, quality of life profile, treatment-related adverse event

Countries

Korea, Republic of

Contacts

Public ContactEunyoung Lee

National Cancer Center

eunyounglee@ncc.re.kr+82-31-920-1682

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026